Abstract
Neuropsychiatric disorders are highly complex conditions and the risk of developing a disorder has been tied to hundreds of genomic variants that alter the expression and/or products (isoforms) made by risk genes. However, how these genes contribute to disease risk and onset through altered expression and RNA splicing is not well understood. Combining our new bioinformatic pipeline IsoLamp with nanopore long-read amplicon sequencing, we deeply profiled the RNA isoform repertoire of 31 high-confidence neuropsychiatric disorder risk genes in human brain. We show most risk genes are more complex than previously reported, identifying 363 novel isoforms and 28 novel exons, including isoforms which alter protein domains, and genes such as ATG13 and GATAD2A where most expression was from previously undiscovered isoforms. The greatest isoform diversity was present in the schizophrenia risk gene ITIH4. Mass spectrometry of brain protein isolates confirmed translation of a novel exon skipping event in ITIH4, suggesting a new regulatory mechanism for this gene in brain. Our results emphasize the widespread presence of previously undetected RNA and protein isoforms in brain and provide an effective approach to address this knowledge gap. Uncovering the isoform repertoire of neuropsychiatric risk genes will underpin future analyses of the functional impact these isoforms have on neuropsychiatric disorders, enabling the translation of genomic findings into a pathophysiological understanding of disease.
Competing Interest Statement
RDP, YP, YY, JG and MBC have received financial support from Oxford Nanopore Technologies (ONT) to present their findings at scientific conferences. ONT played no role in study design, execution, analysis or publication.
Funding Statement
This study was funded by the Leichtung Family through the Brain and Behavior Foundation NARSAD Young Investigator Grant (#27184) awarded to MBC and an Australian National Health and Medical Research Council Investigator Grant (#GNT1196841) awarded to MBC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Ethics Committee of the University of Melbourne gave ethical approval for this work : #12457
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Results & Discussion updated to include further details on highly expressed novel isoforms for KLC1, PTK2B and PRMT7. Supplementary figure on NEGR1 moved to main figures in text (now Fig 7). Limitations updated to expand on long-read amplicons primer positions. Methods moved to after Conclusions. Grammatical and other general errors corrected.
Data Availability
Anonymised raw data will be uploaded to EGA prior to publication to allow access to approved users upon publication. All summarised data will be available upon publication or on request prior to publication.
